Hand–foot syndrome can turn ordinary tasks into negotiations. A hot shower, a walk, opening a jar—suddenly the skin on the palms and soles decides what is possible. For people taking capecitabine, preventing this toxicity is worth a serious conversation.
Topical diclofenac is a conventional anti-inflammatory medicine, not a nutraceutical. It belongs in an integrative evidence library because useful supportive care should follow the data, wherever the intervention comes from.
Evidence at a glance
Population: people starting capecitabine for breast or gastrointestinal cancers. Intervention: preventive topical diclofenac gel. Benefit: fewer moderate-to-severe events in one randomized trial. Counterpoint: a 2026 observational study did not reproduce the benefit. Boundary: prevention of a side effect, not treatment of cancer or established skin injury.
What D-TORCH found
The 2024 D-TORCH phase III trial randomized 264 patients at one center to diclofenac or placebo; 263 were analyzed. Grade 2 or 3 hand–foot syndrome occurred in 3.8% with diclofenac and 15.0% with placebo. The absolute difference was 11.2 percentage points, with a 95% confidence interval of 4.3–18.1.
That corresponds to roughly one fewer affected person for every nine treated over the trial period, calculated from the observed absolute difference. It is a potentially meaningful benefit. It is not a guarantee, and that estimate may change in a population with a different baseline risk.
The published protocol used 1% gel on the palmar and back surfaces of the hands twice daily, for up to 12 weeks. The hand-focused application and assessment matter: we should not assume equivalent protection for the soles, other chemotherapy regimens or longer exposure. This describes research, not instructions to buy gel and begin treatment.
The newer finding deserves equal space
The 2026 DICLO-HFS report followed 151 people with colorectal or gastric cancer at two centers in Türkiye. Seventy-one received preventive 1% diclofenac twice daily and 80 had active monitoring. It found no reduction in grade 2 or worse hand–foot syndrome or delay in onset.
This was observational, so treatment selection and differences in routine care could influence the comparison. It does not cancel a randomized trial. But it does challenge the assumption that the same benefit will appear automatically in everyday practice. A 2025 Japanese trial protocol studies a different 0.1% cream; a protocol is a research plan, not a positive result.
Topical does not mean risk-free
The diclofenac gel prescribing information includes kidney, gastrointestinal bleeding and cardiovascular warnings. NSAID allergy, anticoagulants, other NSAIDs, dehydration and kidney impairment deserve review. Local irritation can occur. Do not apply it to open wounds; its usual arthritis labeling is not an oncology prevention protocol.
Painful peeling or blistering needs a call to the oncology team, not simply another layer of gel. A capecitabine hold or dose adjustment may be needed under the team’s instructions. Preventing toxicity and treating toxicity once it is present are different decisions.
Questions for the care team
- Would this off-label prevention approach fit my regimen and skin condition?
- Which product, application sites and monitoring plan would you use?
- Do my medicines or kidney function change the risk?
- What symptoms should trigger a call or a capecitabine hold under your instructions?
Evidence checked October 13, 2026. Educational review. Explore the Missing Script article library and the podcast—coming soon.
